Guided Therapeutics and I.T.E.M. Medical Technologies Group Announce
Turkish Ministry of Health Sponsored Cervical Cancer Prevention Program
Involving the LuViva® Advanced Cervical Scan
Purchase orders to result in sales of up to $3 million in LuViva devices and disposables
NORCROSS, GA and ANKARA, TURKEY (July 2, 2013) – Guided Therapeutics, Inc.
(OTCBB: GTHP) (OTCQB: GTHP) and its Turkish distributor, I.T.E.M. Medical Technologies Group,
today announced a major program for early detection and prevention of cervical cancer involving Guided
Therapeutics’ LuViva® Advanced Cervical Scan. The program for 2013 and 2014, to be funded by
Turkey’s Ministry of Health, would involve the order and placement of up to $3 million worth of LuViva
Advanced Cervical Scan devices and associated disposables. In addition, the Ministry of Health will
conduct clinical trials to assess the utility of LuViva within a broader national program of cervical cancer
“The selection of the LuViva Advanced Cervical Scan for inclusion in Turkey’s cervical cancer
prevention program is an honor which speaks to the clinical advantages of our technology, including
safety, diagnostic accuracy and economic efficiency,” said Mark L. Faupel, Ph.D., CEO and President of
Guided Therapeutics, Inc. “We look forward to working with I.T.E.M. and the Ministry to improve
health care for all Turkish women.”
Zafer Yazici, CEO and President of I.T.E.M. Medical Technologies Group, added, “We are
pleased to be in a partnership with the Ministry of Health and Guided Therapeutics to bring LuViva into
clinical practice for cervical cancer prevention. The program is consistent with our commitment to bring
advanced medical technologies to this region of the world. We expect that LuViva’s innovative
technology will establish Turkey as a leader in cancer control strategies, while raising the bar in women’s
Under terms of the program, initial shipments are expected to begin this quarter and last through
the end of 2014.
Each year in Turkey, about two million women undergo Pap test screening for cervical cancer,
with as many as 200,000 receiving an abnormal Pap result. Recently, human papillomavirus (HPV)
screening for women was introduced as an alternative to Pap testing. Women who demonstrate either an
abnormal Pap or Positive HPV test are then scheduled for a follow-up exam, called a colposcopy, which
typically includes a painful biopsy of cervical tissue. LuViva is designed to be used before colposcopy to
identify women without disease and prevent them from receiving unnecessary biopsies. Besides the
obvious reduction in patient discomfort, there is also expected to be a reduction in healthcare costs. All of
this is accomplished utilizing a painless test that takes about one minute and produces a result
immediately at the point of care.
About LuViva® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses
spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical
and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as
benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not
require laboratory analysis or a tissue sample, and is designed to provide results immediately, which
eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have
undergone initial screening and are called back for follow up with a colposcopy examination, which in Guided Therapeutics/Turkey MOH
July 2, 2013
many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva®
Cervical Guide single-use, patient interface and calibration disposable.
The LuViva Advanced Cervical Scan is compliant with both Edition 2 and Edition 3 CE
standards, has marketing approval from Health Canada and the Singapore Health Sciences Authority, and
is under U.S. Food and Drug Administration Premarket review.
About I.T.E.M. Medical Technologies Group
I.T.E.M Innovations Group is a leading medical technology consortium in Turkey. The
companies within the I.T.E.M. Group include ROTA ILERI CO. LTD. and NOVATEK CO. LTD., which
were established in 1990 and have successfully introduced an impressive number of innovative medical
technologies to the market. I.T.E.M Innovations Group has been one of the most dynamic, fast growing
and trustworthy medical companies in the region for more than 20 years.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless
testing platform for the early detection of disease based on its patented biophotonic technology that
utilizes light to detect disease at the cellular level. The Company’s first product is the LuViva®
Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a
multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect
cervical cancer up to two years earlier than conventional modalities, according to published reports.
Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer
using the technology platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by
federal law to investigational use. LuViva, the wave logo and “Early detection, better outcomes” are registered
trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or
more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of
products in development, the uncertainty of market acceptance of products, the uncertainty of development or
effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of
capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual
property, as well as those that are more fully described from time to time under the heading “Risk Factors” in
Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for
the fiscal year ended December 31, 2012, and subsequent quarterly reports.